Melanotan II clinical studies have investigated the biological effects of a synthetic melanocortin peptide, particularly its influence on pigmentation, erectile responses, and short-term physiological changes.
Melanotan II (MT-II) is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It interacts with several melanocortin receptors associated with pigmentation and other biological processes.
The compound was initially studied as part of research into synthetic melanotropic peptides. Subsequent investigations identified additional physiological responses, generating interest in its wider receptor pharmacology.
However, despite these findings, the number of published controlled human studies remains small, and Melanotan II has not received FDA approval.
This article reviews the major published human investigations, explains what researchers observed, and identifies important limitations in the available evidence.
Readers seeking foundational information can begin with What Is Melanotan II? A Scientific Overview.
Why Was Melanotan II Investigated?
Melanotan II was developed through research into melanocortin hormones.
Naturally occurring α-MSH participates in melanin-related signaling, while different melanocortin receptor subtypes contribute to several other physiological functions.
Researchers sought to understand how modifying the α-MSH sequence affected peptide potency and receptor interaction.
Melanotan II was developed as a cyclic heptapeptide containing a lactam bridge, which constrains its molecular conformation.
This structural characteristic contributed to its usefulness in melanocortin pharmacology experiments.
Our existing article on Melanotan II structure and molecular properties examines the peptide’s molecular architecture.
Melanotan II Clinical Research: Key Studies
Several early human studies form the foundation of the published clinical literature.
| Publication | Study population | Research area | Main finding |
|---|---|---|---|
| Dorr et al., 1996 | 3 healthy male volunteers | Pigmentation and tolerability | Pigmentation changes in 2 participants |
| Wessells et al., 1998 | 10 men with psychogenic ED | Erectile responses | Greater erectile responses than placebo |
| Wessells et al., 2000 | 10 men with organic ED risk factors | Erectile responses and sexual desire | Increased responses alongside reported adverse effects |
These studies provided evidence of short-term physiological activity.
They were not large enough to establish long-term clinical safety or support general therapeutic use.
Study 1: Melanotan II Phase I Pigmentation Investigation (1996)
One of the earliest published investigations was the 1996 paper:
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
The study was published in Life Sciences by Dorr and colleagues.
Study Design
The investigators enrolled three healthy male volunteers.
The study used a single-blind, placebo-controlled design to examine early physiological responses to experimental Melanotan II administration.
Researchers monitored pigmentation and several other biological effects.
Pigmentation Findings
Two participants developed increased pigmentation in areas including the face, upper body, and buttocks.
Investigators measured changes using quantitative skin reflectance and visual observation.
These findings suggested that Melanotan II could stimulate pigmentation-related pathways in humans.
However, the extremely small sample size made the findings preliminary.
Additional Physiological Observations
The study also reported:
- Nausea.
- Fatigue or somnolence.
- Stretching and yawning.
- Spontaneous erectile responses.
These observations contributed to the scientific interest in Melanotan II beyond pigmentation research.
What Were the Limitations?
Only three individuals participated, and all were male.
The investigation was short-term and could not determine the frequency of uncommon adverse events or the effects of prolonged exposure.
It also did not establish safe clinical use for tanning or other applications.
External research reference: Dorr et al., 1996 — PubMed.
Study 2: Melanotan II and Psychogenic Erectile Dysfunction (1998)
In 1998, Wessells and colleagues investigated Melanotan II in men with psychogenic erectile dysfunction.
The study was published in The Journal of Urology.
Study Design
Ten men participated in a double-blind, placebo-controlled crossover study.
Researchers monitored erectile responses using RigiScan measurements over six hours.
The crossover design allowed investigators to compare responses under experimental and placebo conditions.
Clinical Findings
Eight of the ten participants demonstrated clinically apparent erectile responses following Melanotan II.
Researchers reported a mean duration of penile tip rigidity above 80% of:
- 38 minutes following Melanotan II.
- 3 minutes following placebo.
The difference was statistically significant in this small study.
Adverse Effects
Reported reactions included nausea, stretching, yawning, and decreased appetite.
Although these effects did not require treatment during the investigation, the study did not establish long-term tolerability.
Scientific Interpretation
The findings suggested that melanocortin receptor signaling could influence erectile physiology.
However, the trial enrolled only ten men and evaluated short-term responses.
It did not demonstrate that Melanotan II was appropriate for clinical treatment.
External research reference: Wessells et al., 1998 — PubMed.
Study 3: Melanotan II and Organic Erectile Dysfunction (2000)
A subsequent investigation expanded the research to men with erectile dysfunction associated with organic risk factors.
Published in Urology in 2000, the study evaluated erectile responses, sexual desire, and adverse events.
Study Design
Ten men participated in a placebo-controlled crossover investigation.
The researchers recorded subjective and objective physiological responses.
Main Findings
The investigators reported subjectively observed erections following 12 of 19 Melanotan II administrations, compared with one of 21 placebo administrations.
Increased sexual-desire scores were also reported.
However, adverse effects remained notable.
Nausea, stretching, and yawning were among the reported reactions.
What Did Researchers Conclude?
The findings added to evidence that melanocortin signaling participates in the regulation of erectile responses.
Nevertheless, the small study population and short observation period limited the conclusions.
The results supported continued research into melanocortin pharmacology rather than establishing Melanotan II as an approved therapy.
External research reference: Wessells et al., 2000 — PubMed.
What Do These Human Studies Demonstrate?
Taken together, the early investigations demonstrate that Melanotan II can produce measurable physiological responses in controlled human research settings.
The principal findings include:
1. Evidence of Pigmentation-Related Activity
The 1996 pilot study reported increased pigmentation in two participants.
This observation was consistent with the known involvement of melanocortin receptors in melanin-related pathways.
2. Evidence of Central Physiological Activity
Studies involving men with erectile dysfunction demonstrated responses consistent with the involvement of melanocortin signaling in sexual physiology.
3. Short-Term Adverse Effects
Across the investigations, researchers documented several adverse reactions, particularly nausea and yawning.
4. Limited Clinical Generalizability
The small participant groups, short observation periods, and narrow study populations prevent strong conclusions about long-term clinical outcomes.
These findings should therefore be considered preliminary human pharmacology evidence.
Melanotan II Clinical Studies and Melanocortin Receptors
Understanding the published investigations requires considering the receptors involved.
Melanotan II interacts with multiple melanocortin receptor subtypes.
MC1R and Pigmentation
MC1R plays an important role in melanocyte activity and eumelanin synthesis.
Activation of MC1R can influence intracellular pathways associated with pigmentation.
MC3R and MC4R
MC3R and MC4R participate in central signaling pathways associated with energy regulation and other physiological processes.
Experimental research into melanocortin agonists has helped clarify the role of these receptors.
However, receptor activation observed in laboratory experiments does not automatically establish clinical effectiveness in humans.
MC5R and Peripheral Signaling
MC5R is expressed in several peripheral tissues and contributes to multiple biological functions.
The activity of Melanotan II across several receptor subtypes illustrates its nonselective pharmacological profile.
For more detailed receptor information, see Melanotan II: Mechanism of Action Explained.
Researchers interested in the broader development of these compounds can also consult Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016.
What Have Preclinical Studies Investigated?
Clinical studies represent only a small part of Melanotan II research.
Preclinical investigations have examined the compound in cellular and animal models.
Pigmentation-Related Signaling
Laboratory studies have investigated melanocortin receptor activation and associated melanin synthesis pathways.
Such studies help explain how synthetic melanocortin analogues influence cellular signaling.
Appetite and Energy Regulation
Animal investigations have used melanocortin receptor agonists, including MT-II, to explore pathways related to feeding behavior and energy balance.
These findings should not be interpreted as proof of weight-management benefits in humans.
Receptor Structure and Pharmacology
Melanotan II has also been used in structure-activity research.
Scientists examine how peptide conformation and amino acid modifications affect receptor interactions.
These experiments contribute to understanding melanocortin biology, even when they do not establish direct clinical applications.
Melanotan II Clinical Safety: What Is Known?
One of the largest gaps in Melanotan II research concerns long-term safety.
Early clinical studies were primarily designed to identify initial pharmacological responses.
They were not sufficiently large or prolonged to establish a comprehensive safety profile.
Reported Short-Term Effects
Published studies describe:
- Nausea.
- Fatigue.
- Somnolence.
- Stretching and yawning.
- Appetite changes.
- Spontaneous erectile responses.
Dermatological Questions
Melanotan II influences pigmentation-related signaling, making changes in pigmented skin lesions an important area of concern.
Case reports have described skin abnormalities and melanoma diagnoses following exposure to unapproved melanotan compounds.
However, a temporal association does not prove causation.
Additional research would be required to determine whether particular risks are causally associated with the compound.
Unregulated Compound Quality
Another concern involves the quality and composition of compounds distributed outside regulated pharmaceutical manufacturing systems.
Laboratory research findings cannot be assumed to apply directly to independently manufactured compounds.
The Australian Therapeutic Goods Administration has published safety warnings concerning unapproved melanotan compounds.
How Does Melanotan II Compare With Melanotan 1 in Clinical Research?
Melanotan II is frequently compared with Melanotan 1 because both compounds originate from α-MSH research.
However, there are important differences.
Melanotan 1, also known as afamelanotide, has been evaluated in larger clinical programs for erythropoietic protoporphyria.
Its pharmaceutical implant received FDA approval in 2019 for a defined indication.
Melanotan II has a smaller human evidence base and remains investigational.
Readers interested in the structural and scientific comparison can explore Melanotan 1 vs Melanotan 2: Structural, Receptor, and Research Differences.
The FDA’s Scenesse approval record describes the specific indication authorized for afamelanotide.
Melanotan II in Research-Material Documentation
Published experiments and research-material documentation serve different purposes.
Clinical publications describe findings obtained under particular experimental protocols.
Compound documentation, by contrast, may describe molecular identity, nominal quantity, storage characteristics, or analytical testing.
Orion Peptides maintains a Melanotan II 10 mg research material page containing compound-specific information.
Researchers may also consult the separate Melanotan I (MT1) 5 mg listing when comparing research-material identities.
Neither listing demonstrates that the material is equivalent to a pharmaceutical compound or suitable for human administration.
These distinctions are important when interpreting published research findings.
What Research Gaps Remain?
Despite early findings, multiple unanswered questions remain.
Long-Term Safety
Existing human studies do not establish the safety of repeated or prolonged Melanotan II exposure.
Larger Clinical Populations
The small early studies involved male participants.
Results cannot be generalized to diverse patient populations without additional evidence.
Receptor-Specific Contributions
Further research is needed to clarify how individual melanocortin receptors contribute to observed physiological effects.
Dermatological Outcomes
The relationship between experimental melanocortin signaling, changes in pigmented skin lesions, and long-term dermatological outcomes remains incompletely characterized.
Clinical Risk-Benefit Evaluation
Biological activity alone cannot establish whether a compound has a favorable clinical risk-benefit profile.
That assessment requires well-designed clinical trials examining appropriate endpoints and adverse events.
Frequently Asked Questions
Has Melanotan II been tested in human clinical studies?
Yes. Published early human studies investigated pigmentation, erectile responses, sexual desire, and short-term physiological effects.
What did the first Melanotan II clinical study report?
The 1996 Phase I pilot study found increased pigmentation in two of three participants and recorded several additional physiological responses.
What were the main findings of the 1998 study?
The investigators observed increased erectile responses compared with placebo in a small group of ten men with psychogenic erectile dysfunction.
Are Melanotan II clinical studies sufficient to establish safety?
No. The studies were too small and short-term to establish comprehensive safety or long-term outcomes.
Is Melanotan II FDA approved?
No. Melanotan II has not received FDA approval for human therapeutic use.
Does research on afamelanotide prove Melanotan II is safe?
No. Afamelanotide and Melanotan II differ in structure, pharmacology, and clinical development. Findings involving one compound cannot automatically be applied to the other.
Conclusion
Melanotan II clinical studies have contributed to scientific understanding of pigmentation and melanocortin-related physiological signaling.
The early investigations demonstrated measurable biological activity in small human populations, particularly in pigmentation and erectile response research.
However, these findings remain limited by study size, duration, and the absence of comprehensive long-term safety data.
Melanotan II remains an investigational compound, and its biological activity should not be confused with established clinical safety or approved therapeutic use.
Continued research into melanocortin receptors may expand knowledge of these pathways, but additional controlled evidence is necessary before drawing broader clinical conclusions.
Scientific References
- Dorr RT et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. PubMed.
- Wessells H et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo-controlled crossover study. PubMed.
- Wessells H et al. (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. PubMed.
- Wessells H et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II. PubMed.
- Ericson MD et al. Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016. Full-text review.
- US FDA. Scenesse (Afamelanotide) Approval Information. FDA.
- Therapeutic Goods Administration. Don’t Risk Using Tanning Compounds Containing Melanotan. TGA.
Research disclaimer: This article is intended exclusively for scientific education. It does not recommend administration of Melanotan II or any other unapproved research peptide to humans.
